ATE362772T1 - Vitronektin rezeptor antagonist arzneimitteln oder diagnostika - Google Patents
Vitronektin rezeptor antagonist arzneimitteln oder diagnostikaInfo
- Publication number
- ATE362772T1 ATE362772T1 AT99967442T AT99967442T ATE362772T1 AT E362772 T1 ATE362772 T1 AT E362772T1 AT 99967442 T AT99967442 T AT 99967442T AT 99967442 T AT99967442 T AT 99967442T AT E362772 T1 ATE362772 T1 AT E362772T1
- Authority
- AT
- Austria
- Prior art keywords
- novel compounds
- present
- contrast agent
- treatment
- provides novel
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 102100022337 Integrin alpha-V Human genes 0.000 title 1
- 108010048673 Vitronectin Receptors Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000002961 echo contrast media Substances 0.000 abstract 1
- 230000005251 gamma ray Effects 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
- G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
- G01N25/4806—Details not adapted to a particular type of sample
- G01N25/4813—Details not adapted to a particular type of sample concerning the measuring means
- G01N25/482—Details not adapted to a particular type of sample concerning the measuring means concerning the temperature responsive elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
- G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
- G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
- G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
- B01J2219/00315—Microtiter plates
- B01J2219/00317—Microwell devices, i.e. having large numbers of wells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00495—Means for heating or cooling the reaction vessels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00702—Processes involving means for analysing and characterising the products
- B01J2219/00707—Processes involving means for analysing and characterising the products separated from the reactor apparatus
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Combustion & Propulsion (AREA)
- Animal Behavior & Ethology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11282998P | 1998-12-18 | 1998-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE362772T1 true ATE362772T1 (de) | 2007-06-15 |
Family
ID=22346047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967442T ATE362772T1 (de) | 1998-12-18 | 1999-12-17 | Vitronektin rezeptor antagonist arzneimitteln oder diagnostika |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1140203B1 (de) |
| AT (1) | ATE362772T1 (de) |
| AU (1) | AU2371500A (de) |
| CA (1) | CA2346935A1 (de) |
| DE (1) | DE69936148T2 (de) |
| DK (1) | DK1140203T3 (de) |
| ES (1) | ES2288040T3 (de) |
| PT (1) | PT1140203E (de) |
| TR (1) | TR200101775T2 (de) |
| WO (1) | WO2000035488A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| WO2001098294A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| NZ534500A (en) | 2002-01-24 | 2007-07-27 | Barnes Jewish Hospital | Nanoparticle-based emulsions specifically targeted to integrins |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| GB0305422D0 (en) | 2003-03-10 | 2003-04-16 | Univ Open | Detection, monitoring and treatment of cancer |
| WO2004100996A1 (en) * | 2003-05-12 | 2004-11-25 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals |
| US7319149B2 (en) * | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| US7504088B2 (en) | 2004-06-09 | 2009-03-17 | Kereos, Inc. | Lipophilic derivatives of chelate monoamides |
| WO2006004429A2 (en) * | 2004-07-02 | 2006-01-12 | Ge Healthcare As | Imaging agents comprising a non- peptidic vector linked to a fluorophore via a polyethylene glycol linker |
| HUE057203T2 (hu) | 2013-09-24 | 2022-04-28 | Fujifilm Corp | Új nitrogén-tartalmú vegyület vagy sója, vagy azok fémkomplexe |
| AU2016237099C1 (en) * | 2015-03-25 | 2023-01-19 | Fujifilm Corporation | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same |
| JP6286467B2 (ja) * | 2015-03-25 | 2018-02-28 | 富士フイルム株式会社 | インテグリンが関与する疾患の診断または治療の処置剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0762882A4 (de) * | 1994-06-29 | 2002-09-11 | Smithkline Beecham Corp | Vibronectin-rezeptor-antagonisten |
| GB9511989D0 (en) * | 1995-06-13 | 1995-08-09 | Glaxo Group Ltd | Chemical compounds |
| RU2196769C2 (ru) * | 1995-08-30 | 2003-01-20 | Джи. Ди. Сирл Энд Ко. | Производные аминобензойной кислоты, фармацевтическая композиция |
| JP2000501105A (ja) * | 1995-12-22 | 2000-02-02 | デュポン ファーマシューティカルズ カンパニー | 新規なインテグリン受容体アンタゴニスト |
| ZA978758B (en) * | 1996-10-02 | 1999-03-30 | Du Pont Merck Pharma | Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents |
| WO1998016256A1 (en) * | 1996-10-16 | 1998-04-23 | The Burnham Institute | Magnetic resonance imaging of thrombi |
| WO1999006049A1 (en) * | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
-
1999
- 1999-12-17 AT AT99967442T patent/ATE362772T1/de not_active IP Right Cessation
- 1999-12-17 TR TR2001/01775T patent/TR200101775T2/xx unknown
- 1999-12-17 CA CA002346935A patent/CA2346935A1/en not_active Abandoned
- 1999-12-17 DK DK99967442T patent/DK1140203T3/da active
- 1999-12-17 DE DE69936148T patent/DE69936148T2/de not_active Expired - Fee Related
- 1999-12-17 EP EP99967442A patent/EP1140203B1/de not_active Expired - Lifetime
- 1999-12-17 ES ES99967442T patent/ES2288040T3/es not_active Expired - Lifetime
- 1999-12-17 WO PCT/US1999/030312 patent/WO2000035488A2/en not_active Ceased
- 1999-12-17 AU AU23715/00A patent/AU2371500A/en not_active Abandoned
- 1999-12-17 PT PT99967442T patent/PT1140203E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69936148T2 (de) | 2008-01-24 |
| ES2288040T3 (es) | 2007-12-16 |
| WO2000035488A2 (en) | 2000-06-22 |
| EP1140203B1 (de) | 2007-05-23 |
| CA2346935A1 (en) | 2000-06-22 |
| EP1140203A2 (de) | 2001-10-10 |
| DE69936148D1 (de) | 2007-07-05 |
| AU2371500A (en) | 2000-07-03 |
| DK1140203T3 (da) | 2007-09-10 |
| WO2000035488A3 (en) | 2000-11-09 |
| PT1140203E (pt) | 2007-08-30 |
| TR200101775T2 (tr) | 2002-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000035492A3 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| WO1999058162A3 (en) | Pharmaceuticals for the imaging of angiogenic disorders | |
| WO2000035887A3 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| ATE362772T1 (de) | Vitronektin rezeptor antagonist arzneimitteln oder diagnostika | |
| Weidmann et al. | Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease | |
| US20130004421A1 (en) | Radiolabeled affibody molecules | |
| WO2001098294A3 (en) | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | |
| Grant et al. | Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial | |
| WO2001097861A3 (en) | Vitronectin receptor antagonist pharmaceuticals | |
| Nedrow et al. | Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer | |
| Sharma et al. | Advanced small animal conformal radiation therapy device | |
| WO2001097860A3 (en) | Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy | |
| Gilardi et al. | Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging | |
| ATE414541T1 (de) | Vitronectin rezeptor antagonist pharmaka | |
| Lentle et al. | The scintigraphic findings in Paget's disease of bone | |
| Ocak et al. | 64Cu-Labeled phosphonate cross-bridged chelator conjugates of c (RGDyK) for PET/CT imaging of osteolytic bone metastases | |
| Violet et al. | Prostate‐specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer | |
| DE60033697D1 (de) | Radiomarkierte vip-analoge zur diagnose und therapie | |
| Mankoff et al. | Identification of interleukin-2-induced complete response in metastatic renal cell carcinoma by FDG PET despite radiographic evidence suggesting persistent tumor | |
| Kakkar et al. | Past and present scenario of imaging infection and inflammation: A nuclear medicine perspective | |
| JP2019043892A (ja) | オリゴペプチド誘導体およびそれを用いた医薬 | |
| AR023069A1 (es) | Productos farmaceuticos antagonistas del receptor de vitronectina | |
| Lekakis et al. | Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging | |
| Mango et al. | Hybrid Technology: From Cars to Diagnosis | |
| Ensign et al. | Malignant Glioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1140203 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |